US 12,465,613 B2
Pharmaceutical composition for use in the prophylactic and/or therapeutic treatment of L-DOPA-induced dyskinesia
Ana M. Munoz Patino, Santiago de Compostela (ES); Jose Luis Labandeira Garcia, Santiago de Compostela (ES); and Andrea Lopez Lopez, Santiago de Compostela (ES)
Assigned to UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, Santiago de Compostela (ES)
Filed by UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, Santiago de Compostela (ES)
Filed on Mar. 22, 2022, as Appl. No. 17/701,391.
Application 17/701,391 is a continuation of application No. 17/406,689, filed on Aug. 19, 2021, granted, now 11,337,985.
Application 17/406,689 is a continuation of application No. PCT/ES2020/070482, filed on Jul. 24, 2020.
Claims priority of application No. P201930713 (ES), filed on Jul. 31, 2019.
Prior Publication US 2022/0211719 A1, Jul. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/551 (2006.01); A61K 31/198 (2006.01); A61P 25/14 (2006.01)
CPC A61K 31/551 (2013.01) [A61K 31/198 (2013.01); A61P 25/14 (2018.01)] 27 Claims
 
1. A method for treating dyskinesias induced by L-DOPA in a Parkinson's disease patient comprising orally administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of fasudil or hydroxy fasudil or a pharmaceutically acceptable salt thereof.